The stock of Matinas BioPharma Holdings Inc. (AMEX:MTNB) last traded at $0.45, down -2.56% from the previous session.
Data from the available sources indicates that Matinas BioPharma Holdings Inc. (AMEX:MTNB) is covered by 3 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $2.00, we find $3.00. Given the previous closing price of $0.46, this indicates a potential upside of 552.17 percent. MTNB stock price is now -15.35% away from the 50-day moving average and -35.00% away from the 200-day moving average. The market capitalization of the company currently stands at $100.34M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
In total, 0 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $2.67 as their price target over the next twelve months.
, while ‘SunTrust’ rates the stock as ‘Buy’.
Insiders disposed of 1,358,122 shares of company stock worth roughly $0.61 million over the past 1 year. A total of 3.81% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MTNB stock. A new stake in Matinas BioPharma Holdings Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $107,000. GLOBAL RETIREMENT PARTNERS, LLC invested $62,000 in shares of MTNB during the first quarter. In the first quarter, BLEAKLEY FINANCIAL GROUP, LLC acquired a new stake in Matinas BioPharma Holdings Inc. valued at approximately $27,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in MTNB for approximately $20,000. GOLDMAN SACHS GROUP INC purchased a new stake in MTNB valued at around $16,000 in the second quarter. In total, there are 58 active investors with 13.00% ownership of the company’s stock.
With an opening price of $0.4700 on Monday morning, Matinas BioPharma Holdings Inc. (AMEX: MTNB) set off the trading day. During the past 12 months, Matinas BioPharma Holdings Inc. has had a low of $0.43 and a high of $1.00. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.60, and a quick ratio of 7.60. The fifty day moving average price for MTNB is $0.5259 and a two-hundred day moving average price translates $0.6850 for the stock.
The latest earnings results from Matinas BioPharma Holdings Inc. (AMEX: MTNB) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.03, inline with analysts’ expectations of -$0.03. This compares to -$0.03 EPS in the same period last year. For the current quarter, analysts expect MTNB to generate $1.07M in revenue.
Matinas BioPharma Holdings Inc.(MTNB) Company Profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead’s antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
